shoe, <specify>
thuasne pacific pty ltd -
40508 - shoe,
shoe, cast
zimmer biomet pty ltd - 10668 - shoe, cast - shoe worn over cast to protect the cast material and provide support.
torque wrench, manual, dental
pacific dental specialties pty ltd - 44901 - torque wrench, manual, dental - this is a hand held manual device with an appropriate torque dental and/or retaining screws fitted into the oral cavity during dental surgical procedures.
madopar
roche products (nz) ltd - benserazide hydrochloride 28.5mg equivalent to to 25 mg benserazide base; levodopa 100mg; - capsule - 125 mg - active: benserazide hydrochloride 28.5mg equivalent to to 25 mg benserazide base levodopa 100mg excipient: gelatin indigo carmine iron oxide red magnesium stearate microcrystalline cellulose povidone purified talc titanium dioxide - madopar is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism.
madopar
roche products (nz) ltd - benserazide hydrochloride 57mg equivalent to to 50 mg benserazide base; levodopa 200mg; - capsule - 250 mg - active: benserazide hydrochloride 57mg equivalent to to 50 mg benserazide base levodopa 200mg excipient: gelatin indigo carmine iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose povidone purified talc titanium dioxide - madopar is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism.
madopar
roche products (nz) ltd - benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base; levodopa 50mg; - capsule - 62.5 mg - active: benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base levodopa 50mg excipient: gelatin indigo carmine iron oxide black magnesium stearate mannitol microcrystalline cellulose povidone purified talc titanium dioxide - madopar is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism.
madopar rapid 62.5
roche products (nz) ltd - benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base; levodopa 50mg; - dispersible tablet - 62.5 mg - active: benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base levodopa 50mg excipient: citric acid magnesium stearate maize starch microcrystalline cellulose - madopar rapid is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism. madopar rapid is a formulation which is suitable for patients with dysphagia (difficulties in swallowing) or who require a formulation with a more rapid onset of action, e.g. patients suffering from early morning and afternoon akinesia, or who exhibit "delayed on" or "wearing off" phenomena.
madopar hbs
roche products (nz) ltd - benserazide hydrochloride 28.5mg equivalent to to 25 mg benserazide base; levodopa 100mg; - modified release capsule - 125 mg - active: benserazide hydrochloride 28.5mg equivalent to to 25 mg benserazide base levodopa 100mg excipient: calcium hydrogen phosphate dihydrate gelatin hydrogenated vegetable oil hypromellose indigo carmine iron oxide yellow magnesium stearate mannitol povidone purified talc titanium dioxide - madopar hbs is indicated for patients presenting with all types of fluctuation in response, especially those related to fluctuations in plasma levels (i.e. "peak dose dyskinesia" and "end of dose deterioration") and for better control of nocturnal symptoms
motetis
douglas pharmaceuticals limited - tetrabenazine 25mg - tablet - 25 mg - active: tetrabenazine 25mg excipient: iron oxide yellow lactose monohydrate magnesium stearate pregelatinised maize starch purified talc - tetrabenazine is indicated for the treatment of moderate to severe tardive dyskinesia, which is disabling and/or socially embarrassing. the condition should be persistent despite withdrawal of antipsychotic therapy, or in cases where withdrawal of antipsychotic medication is not a realistic option; also where the condition persists despite reduction in dosage of antipsychotic medication or switching to atypical antipsychotic medication.
xenazine 25
aft pharmaceuticals ltd - tetrabenazine 25mg; ; - tablet - 25 mg - active: tetrabenazine 25mg excipient: iron oxide yellow lactose monohydrate magnesium stearate purified talc starch - movement disorders associated with organic central nervous system conditions, e.g. huntington's chorea, hemiballismus and senile chorea. tetrabenazine is also indicated for the treatment of moderate to severe tardive dyskinesia, which is disabling and/or socially embarrassing. the condition should be persistent despite withdrawal of antipsychotic therapy, or in cases where withdrawal of antipsychotic medication is not a realistic option; also where the condition persists despite reduction in dosage of antipsychotic medication or switching to atypical antipsychotic medication.